Eli Lilly (United Kingdom)

Recent papers from Eli Lilly (United Kingdom)

1. Pharmacokinetic Drug–Drug Interactions of Imlunestrant in Healthy Female Participants of Nonchildbearing PotentialClinical and Translational Science · 2026
2. Characterising patients with Alzheimer’s disease in England: a cohort study using data from Clinical Practice Research Datalink linked to Hospital Episode StatisticsBMJ Open · 2026
3. LY3410738, a Covalent Inhibitor of Mutant IDH1/2, is Effective in Acute Myeloid Leukemia Preclinical ModelsBlood Cancer Discovery · 2026
4. Evaluation of Pharmacokinetics and Safety of Imlunestrant in Participants with Hepatic ImpairmentThe Journal of Clinical Pharmacology · 2026
5. SURMOUNT ‐ REAL UK : A Pragmatic Randomized Clinical Trial to Assess the Effectiveness of Tirzepatide in Adults With ObesityObesity · 2026
6. Healthcare Provider Awareness and Perspectives on Obesity: A Survey Across Medical SpecialtiesObesity Science & Practice · 2026
7. Supporting Weight Management for Kidney Transplant Candidates in People With Obesity on Haemodialysis: The First National Survey of UK Kidney Healthcare ProvidersDiabetes Obesity and Metabolism · 2026
8. Impact of Obesity on Individuals in Saudi Arabia: A Real-World Patient and Physician SurveyAdvances in Therapy · 2026
9. Effect of Mirikizumab on Clinical and Endoscopic Outcomes Based on Prior Advanced Therapy Failure in Patients With Moderately to Severely Active Ulcerative ColitisUnited European Gastroenterology Journal · 2026
10. P166 High body mass index psoriasis is associated with higher prevalence of cardiometabolic disease, psoriatic arthritis, and systemic inflammationLara D. Veeken · 2026
11. E139 Disease burden and comorbidities in patients with psoriatic arthritis and concomitant obesity - a pooled analysis of three clinical trialsLara D. Veeken · 2026
12. E140 Perceptions of living with and managing both psoriatic disease and overweight/obesity: a qualitative interview studyLara D. Veeken · 2026
13. E141 Obesity is associated with higher disease activity and lower health-related quality of life in psoriatic arthritis treatment respondersLara D. Veeken · 2026
14. Reversion to normoglycemia with tirzepatide vs semaglutide in participants with obesity and prediabetes: a post hoc analysis of SURMOUNT-5Journal of Endocrinological Investigation · 2026
15. Annual pharmacy cost per patient achieving composite treatment endpoints: a cost to target analysis of tirzepatide versus subcutaneous semaglutide 1 mg in patients with type 2 diabetes in the UK.2026
16. Trop-2.2 directed radioimmunotherapy with 177Lu, 225Ac, and 212Pb in a pancreatic cancer modelClinical Cancer Research · 2026
17. Efficacy of Pirtobrutinib Monotherapy in Treatment-Naïve Chronic Lymphocytic Leukemia: A Bayesian Network Meta-Analysis of Randomized Controlled TrialsCancers · 2026
18. ‘There is more to life than HbA 1c ’: A comprehensive qualitative framework from the Hypo‐ RESOLVE project evidencing the impacts of hypoglycaemia on the quality of life of adults living with type 1 or type 2 diabetesDiabetic Medicine · 2026
19. P0743Demonstration of real-world treatment patterns and persistence among patients with moderately to severely active Ulcerative Colitis initiating mirikizumab: A population-based observational study from DenmarkJournal of Crohn s and Colitis · 2026
20. P0200Mirikizumab, guselkumab, and risankizumab did not differ in remission efficacy adjusting for imbalanced treatment discontinuation in network meta-analysis of treat-through trials for Crohn’s diseaseJournal of Crohn s and Colitis · 2026